GeoVax Labs, Inc. (Nasdaq: GOVX) announced a strategic portfolio prioritization, concentrating resources on its lead programs GEO-MVA and Gedeptin while discontinuing active development of its GEO-CM04S1 COVID-19 vaccine candidate. The decision, disclosed in a press release, reflects the company's alignment with programs demonstrating clearer regulatory pathways, stronger demand visibility, and more immediate commercialization potential.
The discontinuation of the COVID-19 vaccine program was not due to safety concerns but rather the continued evolution and contraction of the global COVID-19 vaccine market. GeoVax emphasized that portfolio prioritization is standard in biotechnology, enabling companies to focus on highest-value opportunities as market conditions evolve.
GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate targeting mpox and smallpox, is advancing under an expedited regulatory pathway supported by European Medicines Agency (EMA) scientific advice. Potential approval could be based on a single pivotal immunobridging study demonstrating non-inferiority to an approved MVA vaccine, accelerating timelines and reducing clinical risk. Clinical-grade material has been manufactured and released for the planned Phase 3 study, after which GEO-MVA could move toward regulatory submission and potential Emergency Use Licensing.
GeoVax has initiated outreach with global procurement and preparedness stakeholders, including government agencies and biodefense programs, to support potential vaccine supply agreements. These efforts position GEO-MVA as a critical additional supplier for national stockpiling and outbreak response, enhancing supply-chain resilience.
In oncology, Gedeptin, a gene-directed enzyme prodrug therapy (GDEPT) platform, is being advanced in line with emerging immuno-oncology paradigms. The planned Phase 2 study (AdPNP-203) will evaluate Gedeptin in combination with pembrolizumab and fludarabine in a neoadjuvant setting for head and neck cancers. Gedeptin's mechanism generates a potent chemotherapeutic agent locally within tumors, sensitizing them to checkpoint inhibitors by exposing neoantigens. This may improve response rates and durability in patients with limited benefit from checkpoint inhibition alone, aligning with results from the KEYNOTE-689 Phase 3 trial showing improved event-free survival with neoadjuvant checkpoint inhibitor therapy.
David Dodd, Chairman and CEO of GeoVax, stated, “GeoVax is at an important inflection point, and this decision reflects a deliberate and disciplined focus on the programs we believe can deliver the greatest near-term and long-term value.” He added that concentrating efforts on GEO-MVA and Gedeptin positions the company for a focused, execution-driven path toward late-stage development and commercialization.
For more information, visit GeoVax's website.
